Cancers, Vol. 16, Pages 344: Ocular Surface Side Effects of Novel Anticancer Drugs

Cancers, Vol. 16, Pages 344: Ocular Surface Side Effects of Novel Anticancer Drugs Cancers doi: 10.3390/cancers16020344 Authors: Livio Vitiello Filippo Lixi Giulia Coco Giuseppe Giannaccare Surgery, anticancer drugs (chemotherapy, hormonal medicines, and targeted treatments), and/or radiation are common treatment strategies for neoplastic diseases. Anticancer drugs eliminate malignant cells through the inhibition of specific pathways that contribute to the formation and development of cancer. Given the ability of such pharmacological medications to combat cancerous cells, their role in the management of neoplastic diseases has become essential. However, these drugs may also lead to undesirable systemic and ocular adverse effects due to cyto/neuro-toxicity and inflammatory reactions. Ocular surface side effects are recognized to significantly impact patient’s quality of life and quality of vision. Blepharoconjunctivitis is known to be a common side effect caused by oxaliplatin, cyclophosphamide, cytarabine, and docetaxel, while anastrozole, methotrexate, and 5-fluorouracil can all determine dry eye disease. However, the potential processes involved in the development of these alterations are yet not fully understood, especially for novel drugs currently available for cancer treatment. This review aims at analyzing the potential ocular surface and adnexal side effects of novel anticancer medications, trying to provide a better understanding of the un...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research